- Case report
- Open Access
Consequences of inadvertent intravitreal Mitomycin C injection
© The Author(s) 2018
- Received: 8 November 2017
- Accepted: 16 January 2018
- Published: 12 February 2018
Mitomycin C (MMC) as an alkylating agent is miscellaneous an antineoplastic, antibiotic and ophthalmic agent. Here we aim to report a case of inadvertent intravitreal MMC injection instead of Avastin in case of diabetic macular edema.
A 53 years old woman was planned to receive intravitreal Avastin injection, but accidentally, 0.05 ml of MMC 0.2% was injected. Best corrected visual acuity (BCVA) was 20/160 before injection. After 2 days, patient was referred to a tertiary referral eye center. BCVA was hand motion at presentation. Intraocular pressure was 4 mmHg. In slit lamp exams, conjunctival injection, corneal edema, Descemet fold, anterior chamber and anterior vitreous cells were presented. Pars plana vitrectomy with peripheral vitreous shaving and silicone oil tamponade was performed. Electroretinography showed undetectable responses. Ultrasound biomicroscopy showed ciliary body shortening and detachment. Optical coherent tomography showed diffuse retinal edema the day after surgery, subretinal fluid pockets in 2 weeks, and atrophy with undetectable and intertwined layers 2 months later. Gradually, like the retina, iris became atrophic and pigments were dispersed diffusely over the lens and endothelium.
MMC is showed to be severely toxic to intraocular tissues. In our case, iris and ciliary body became atrophic. Ciliary body detachment induced hypotony. Moreover, MMC induces retinal necrosis and atrophy. Visual outcome is profoundly poor.
- Mitomycin C
- Retinal toxicity
- Intravitreal injection
Mitomycin C (MMC) is miscellaneous an antineoplastic, antibiotic and ophthalmic agent. It acts as an alkylating agent and produces DNA cross-linking, mostly on guanine and cytosine pairs, inhibiting synthesis of DNA and RNA and degrading DNA by nuclear lysis and formation of giant cells. MMC has its maximum effect against cells in late G and early S phases . In glaucoma filtration surgeries, MMC applied topically, and is believed to alter conjunctival vascular endothelium and inhibit fibroblast proliferation . Systemic absorption following ocular administration is unknown, however, it should be far lower than when it is administered parenterally as a chemotherapy agent . The use of MMC in keratorefractive surgeries became widespread as it effectively reduced haze formation after surgery and improve the predictability of visual outcomes following refractive surgery . Moreover, in glaucoma and pterygium surgeries, topical solution is applied by sponges to surgical site, usually for 2 min .
Lenticular changes and cataract is reported in topical applications . Inadvertent corneal and/or scleral damage, including thinning or perforation, may occur with use of MMC solution in concentrations > 0.2 mg/mL or for time periods > 2 min . There are several reports of complications after MMC usage even many years after topical application of the drug [4, 5]. As a result, many studies were designed to evaluate the effect of MMC usage in refractive surgery on the corneal endothelium. Some studies have reported significant corneal endothelial toxicity, while others failed to detect significant change in corneal endothelial density or morphology .
Previous reports were focused on topical application of the MMC. Here we report accidental intravitreal MMC injection in a case of diabetic macular edema instead of Bevacizumab.
A 53 years old woman with diabetic macular edema in her right eye and decreased vision to 20/160 was recommended to have an intravitreal bevacizumab injection. In the operating theater, however, 0.05 ml of 0.2% Mitomycin C solution inadvertently was injected intravitreally. The ophthalmologist immediately referred the patient to the emergency department of a tertiary referral center for urgent vitrectomy, but the patient presented to the hospital 2 days later. Due to the distance, she came late till visual loss became severe.
At presentation, visual acuity was hand motion (HM), with relative afferent pupillary defect (RAPD). In slit lamp exam, conjunctival injection, corneal edema with Descemet fold, and deep anterior chamber with inflammatory cell was seen. Intraocular pressure (IOP) was 4 mmHg. Cataract was nuclear sclerosis, and red reflex was reduced. Anterior vitreous cell was observed. Optic disc was round in shape, erythematosus, with sharp borders and cup/disc ratio of 0.4. Fundus exam revealed macular edema with hard exudates and diabetic retinopathy as mild to moderate non proliferative diabetic retinopathy. Visual acuity of her left eye was 20/20 with mild non proliferative diabetic retinopathy.
23 gauge pars plana deep vitrectomy with posterior vitreous detachment induction and peripheral vitreous shaving was performed. Retinal venular tortuosity, arterial narrowing and diffuse retinal edema were seen. No retinitis or infarction was observed. As the patient was hypotonic, silicone oil tamponade was used. Sclerotomies were sutured and subtenon triamcinolone acetonide (TriamHEXAl, Hexal AG, Holzkirchen, Germany) was injected.
Mitomycin C is mainly as an alkylating agent. MMC has a variety of specific biological effects in mammalian cells, including selective inhibition of DNA synthesis, mutagenesis, and stimulation of genetic recombination, chromosome breakage. Although DNA alkylation may occur at any stage in the cell cycle, it affects DNA synthesis, particularly during the late G1 and S phases . MMC, therefore, works as a genotoxic antibiotic, and at high concentrations, cellular RNA and protein syntheses are also suppressed . Therefore, it induces apoptosis and necrosis in high doses.
In an electroretinography and also histopathologic study, Kawashima et al. evaluate the retinal toxicity of MMC injection in the rat eye. Three different concentrations of MMC (0.2, 0.3 and 0.4 mg/ml) were injected into either the vitreous cavity or the anterior chamber of the experimental eyes. A full-field electroretinogram was recorded before injection and 2, 4 and 7 days after injection. The retinas of all eyes were examined by light and electron microscopy. They have found no evidence of electroretinography and histologic changes 2 and 7 days after injection of 0.4 mg/ml of MMC into the anterior chamber. However, profound electroretinography changes did follow injection of the drug into the vitreous. These were absent with the 0.2-mg/ml solution at 7 days, mild with the 0.3-mg/ml solution at 7 days and profound with the 0.4-mg/ml solution as early as 2 days. Intravitreal injection of 0.4 mg/ml, however, showed selective degeneration of Müller cell process at day 2, retinal pigment epithelium changes at day 4 and irregular arrangement of the outer nuclear layer and photoreceptors at day 7. It was concluded that intravitreal injection of MMC in high doses, as used as routine clinical doses, could cause retinal functional and histological disorders .
In a case report, Nuyts et al. claimed that there is a correlation between diffusion of MMC into the vitreous cavity and retinal vasculature occlusion. In a 45-year-old male who underwent a trabeculectomy with MMC for a secondary glaucoma after complicated cataract surgery, due to early bleb failure, a needling procedure with subconjunctival injection of MMC was performed. Five days postoperatively, a combined occlusion of both central retinal artery and vein occlusion occurred. They have concluded that a relation between the diffusion of MMC into the vitreous cavity, because of opening of the posterior capsule, and the development of retinal toxicity may exist .
In this case report, we have reported the outcomes of inadvertent intravitreal MMC injection. MMC application in the ophthalmology have been evaluated mostly in the field of ocular surface and orbital surgeries. Reported side effects in this issue is limited mostly on ocular surfaces or corneal endothelium or cataract formation. The only available report was in a case who had undergone vitrectomy after injection. In that case the patient suffered cystoid macular edema, iris atrophy and mild corneal temporal edema 6 months after vitrectomy. It was a photo essay and comprehensive report of that case was not available . In our patient, due to distance, patient was referred late to our center. Although we performed vitrectomy less than 4 h from the first visit, retina became necrotic and atrophic. In early phase retinal edema converted to intraretinal hemorrhages. Electroretinography was undetectable since the early phase. Gradually IOP decreased and subretinal fluid pocket were appeared. Iris became atrophic and pigments dispersed in the anterior chamber. Although we performed deep vitrectomy, used long term topical and subtenon corticosteroid, and also cycloplegic, no one could arrest the inflammatory and destructive effects of intravitreal injection of MMC. One year follow up also showed toxic effects of MMC or inflammatory responses, continued to affect the ocular tissues. Lens became cataractous and iris became atrophied. As electroretinography showed, the MMC may affect retina very soon. It also affects profoundly on uveal tissue as iris atrophy progresses and iris became atrophic.
All the authors contributed significantly to this case report, and all authors agree to be accountable for all aspects of the work. All authors contributed equally in acquisition of clinical data about the patient and preparing the draft of the manuscript. MA performed the vitrectomy under the supervision of AL contributed in revising and finalizing the manuscript. All authors read and approved the final manuscript.
The authors would like to thank Roghayeh Shafei B.A. and Alireza Haddadpour B.Sc., Audiovisual Department, and Leyla Javdane B.Sc. and Maryam Nemati Soldarogh B.Sc., Angiography Department of Farabi Eye Hospital for their help in the process of this report. It is a pleasure for us to appreciate kindness of Ms. Mahbobeh Najafi M.Sc.
The authors declare that they have no competing interests.
Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.
Consent for publication
Written and comprehensive informed consent were obtained from the patient and she agreed to publish her data anonymously.
Ethics approval and consent to participate
The patient was completely notified about the procedure, and signed the written informed consent.
The authors received no funding. It is the authors’ own work, not funded by government or academicals institutes.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Lockwood A, Brocchini S, Khaw PT. New developments in the pharmacological modulation of wound healing after glaucoma filtration surgery. Curr Opin Pharmacol. 2013;13(1):65–71.View ArticlePubMedGoogle Scholar
- Bindlish R, Condon GP, Schlosser JD, D’Antonio J, Lauer KB, Lehrer R. Efficacy and safety of mitomycin-C in primary trabeculectomy: five-year follow-up. Ophthalmology. 2002;109(7):1336–41.View ArticlePubMedGoogle Scholar
- Schipper I, Suppelt C, Gebbers JO. Mitomycin C reduces scar formation after excimer laser (193 nm) photorefractive keratectomy in rabbits. Eye (Lond). 1997;11:649–55.View ArticleGoogle Scholar
- Wan Norliza WM, Raihan IS, Azwa JA, et al. Scleral melting 16 years after pterygium excision with topical Mitomycin C adjuvant therapy. Cont Lens Anterior Eye. 2006;29(4):165–7.View ArticlePubMedGoogle Scholar
- Tsai YY, Lin JM, Shy JD. Acute scleral thinning after pterygium excision with intraoperative mitomycin C: a case report of scleral dellen after bare sclera technique and review of the literature. Cornea. 2002;21(2):227–9.View ArticlePubMedGoogle Scholar
- Teus MA, de Benito-Llopis L, Alió JL. Mitomycin C in corneal refractive surgery. Surv Ophthalmol. 2009;54(4):487–502.View ArticlePubMedGoogle Scholar
- Kawashima S, Mizota A, Adachi-Usami E, Kimura T. Effects of mitomycin C on the rat retina. Doc Ophthalmol. 1996–1997;92(3):229–41.Google Scholar
- Verweij J, Pinedo HM. Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs. 1990;1:5–13.View ArticlePubMedGoogle Scholar
- Tomasz M. Mitomycin C: small, fast and deadly (but very selective). Chem Biol. 1995;2:575–9.View ArticlePubMedGoogle Scholar
- Nuyts RM, Van Diemen HA, Greve EL. Occlusion of the retinal vasculature after trabeculectomy with mitomycin C. Int Ophthalmol. 1994;18(3):167–70.View ArticlePubMedGoogle Scholar
- Ryoo NK, Kim MK, Wee WR. Consequences of accidental mitomycin C intraocular injection. JAMA Ophthalmol. 2013;131(9):1197.View ArticlePubMedGoogle Scholar